Medline shares are down about 3% as traders refocus on near-term supply and headline risk. A large sponsor-led secondary offering closed recently, adding a major block of stock to the market at $41.00 per share and reinforcing concerns that additional selling by large holders could cap upside in the near term. (ir.medline.com)

The company closed a secondary offering of 86,250,000 shares of Class A common stock at $41.00 per share, including the underwriters’ full option exercise. Importantly, Medline did not sell shares in the transaction and did not receive proceeds, which can make the trade read as incremental liquidity for existing sponsors rather than a balance-sheet catalyst for the business. (ir.medline.com)

Separately, Medline is facing renewed attention on regulatory and quality-system execution after an FDA warning letter related to NAMIC angiographic control syringes and manifolds. The warning-letter headlines have elevated questions about potential remediation work, oversight intensity, and whether any additional actions (such as broader corrective measures) could affect certain product lines. (medicaldevice-network.com)

Investors will watch for (1) any follow-through selling now that a large block has been distributed, (2) updates on Medline’s response and remediation timelines connected to the FDA warning letter, and (3) whether the stock can hold above recent post-offering levels as liquidity increases. (ir.medline.com)